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Bertrand Courtioux,§ Élisa Boutet-Robinet,# Marc Since,∇ Rachel Milne,○ Susan Wyllie,○
Alan H. Fairlamb,○ Alexis Valentin,⊥ Pascal Rathelot,† Pierre Verhaeghe,*,∥ Patrice Vanelle,†
and Nadine Azas‡
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ABSTRACT: Twenty nine original 3-nitroimidazo[1,2-a]-
pyridine derivatives, bearing a phenylthio (or benzylthio)
moiety at position 8 of the scaﬀold, were synthesized. In vitro
evaluation highlighted compound 5 as an antiparasitic hit
molecule displaying low cytotoxicity for the human HepG2
cell line (CC50 > 100 μM) alongside good antileishmanial
activities (IC50 = 1−2.1 μM) against L. donovani, L. infantum,
and L. major; and good antitrypanosomal activities (IC50 =
1.3−2.2 μM) against T. brucei brucei and T. cruzi, in
comparison to several reference drugs such as miltefosine,
fexinidazole, eﬂornithine, and benznidazole (IC50 = 0.6 to 13.3
μM). Molecule 5, presenting a low reduction potential (E° =
−0.63 V), was shown to be selectively bioactivated by the L. donovani type 1 nitroreductase (NTR1). Importantly, molecule 5
was neither mutagenic (negative Ames test), nor genotoxic (negative comet assay), in contrast to many other nitroaromatics.
Molecule 5 showed poor microsomal stability; however, its main metabolite (sulfoxide) remained both active and
nonmutagenic, making 5 a good candidate for further in vivo studies.
KEYWORDS: Leishmania ssp, imidazopyridine, nitroaromatic, nitroreductases, Ames test, comet assay
Trypanosomatids are ﬂagellated protozoan parasites thatbelong to the Kinetoplastid order. These unicellular
parasites are responsible for several vector borne diseases in
mammals. Among the trypanosomatids, Leishmania spp and
Trypanosoma spp are the two main parasites encountered in
human pathology and responsible for lethal infections: visceral
leishmaniasis (VL),1 human African trypanosomiasis (HAT),2
or Chagas disease (CD).3 These neglected tropical diseases
threaten millions of people worldwide with current total deaths
estimated at 30,000 per annum, mainly in tropical and
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subtropical areas.4 New eﬃcient, safe, and cheap oral anti-
Kinetoplastid agents are urgently needed due to the major
limitations of the few currently available drugs (i.e., toxicity,
mode of administration, cost) and the emergence of resistant
parasites (mainly toward antimony derivatives and miltefo-
sine).5 In this context, small azaheterocyclic molecules,
including imidazo[1,2-a]pyridine derivatives,6 are studied to
enrich the antitrypanosomatid drug discovery pipeline.7,8
Recently, nitroaromatic molecules, such as fexinidazole9 and
delamanid,10 showed a renewed interest against infectious
diseases such as HAT, VL, CD, and even tuberculosis.11
Indeed, these compounds act as prodrugs, requiring the
bioactivation of their nitro group into reduced reactive
intermediates, in order to display their antiparasitic properties.
This bioactivation step is catalyzed by nitroreductases (NTR),
enzymes found in some bacteria and parasites, but not in
mammalian cells. Thus, the concept of exploiting NTR to
activate prodrugs is an attractive strategy to target selectively
pathogen parasites and bacteria.
Two NTRs have been identiﬁed and characterized in
Leishmania spp: (i) an essential mitochondrial type 1 NTR
(NTR1)12 catalyzing a two-electron reduction reaction and
that bioactivates 5-nitroimidazoles like fexinidazole13,14 and
(ii) a cytosolic type 2 NTR (NTR2)15 catalyzing a
monoelectronic reduction reaction. NTR2 more particularly
activates bicyclic nitroheterocycles containing a 4-nitro-
imidazole moiety, such as delamanid and pretomanid.16 In
Trypanosoma brucei spp, only the type 1 NTR was discovered,
mediating the bioactivation of the nitroaromatic drugs
benznidazole17 and nifurtimox.18 To date, the structures of
parasitic NTRs remain unknown, as no X-ray diﬀraction data is
available. Thus, drug design techniques such as docking cannot
be applied for designing new NTR substrates.
Previously, we reported the antileishmanial activity of 3-
nitroimidazo[1,2-a]pyridine derivatives. After identifying a hit
molecule bearing bromine atoms at positions 6 and 8 of the
imidazopyridine ring (hit A),19 a pharmacomodulation study
led to a series of 8-aryl-6-chloro-3-nitroimidazo[1,2-a]-
pyridines that displayed an improved activity against
Leishmania spp and Trypanosoma b. brucei,20 suggesting the
key role of the substituent at position 8 of the scaﬀold (Figure
1).
In a continuation of this project, we wanted to explore the
inﬂuence of the insertion of a heteroatomic bridge between the
imidazopyridine ring and an aryl group at position 8, using a
synthetic route to functionalize antiparasitic azaheterocycles by
a phenylthio moiety.21,22 We applied this synthetic procedure
to a previously described substrate: 8-bromo-6-chloro-3-nitro-
2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridine.20 Twenty-six
original nitroaromatic derivatives bearing a sulfur group at
position 8 were then synthesized, using various thiophenol or
benzylthiol reagents. The majority of these compounds were
prepared with moderate to good yields (58−95%). The use of
disubstituted thiophenols (compounds 20−22) led to lower
yields (31−38%).
All synthesized molecules were ﬁrst screened in vitro against
the promastigote form of L. donovani and potencies were
compared to those achieved with commercial reference drugs
(i.e., amphotericin B, miltefosine, and pentamidine) along with
drug-candidate fexinidazole (Table 1). To assess antiparasitic
selectivity, the cytotoxicity of all compounds was measured
against the HepG2 human cell line, using doxorubicin as
control.
About half of the tested molecules showed poor solubility in
the culture medium and could not be tested against the HepG2
cell line above 4−6 μM. This is particularly noted with the four
benzylthioether derivatives 23 to 26, which could not be
tested. Three compounds (10, 18, and 20) showed moderate
solubility in the culture medium, ranging from 15.6 to 25 μM.
Finally, four molecules, all presenting a para-substituted
thiophenyl moiety, showed satisfactory CC50 values, above
50 μM, indicating both good solubility in the culture medium
and a low cytotoxicity on the tested cell line. Among the 22
molecules evaluated on the promastigote stage of L. donovani,
only compound 19 was found to be devoid of antileishmanial
activity, perhaps due to its charged carboxylate group. The
active molecules display IC50 values ranging between 1.0 and
2.3 μM, slightly lower than miltefosine and comparable to
fexinidazole. Two compounds (2 and 5) functionalized with a
p-halophenylsulfane group are particularly promising and can
be considered as hit compounds, with respective selectivity
index of >62.5 and >100 (2 to 4 times better than miltefosine).
The 3D structure of hit compound 5 was conﬁrmed by X-ray
diﬀraction (see Supporting Information).
A secondary screening was conducted on hit molecules 2
and 5, against the intramacrophage amastigote stage of L.
donovani and L. major, on the promastigote stage of L. major
and on L. infantum axenic amastigotes. The CC50 values for
these molecules (Table 2) were also determined against THP1
monocyte cell line. None of these compounds showed
cytotoxic eﬀects on THP1 cells up to 62.5 μM. Molecule 5
showed the best activities against intracellular L. donovani and
L. major amastigotes (IC50 values of 1.3 and 2.1 μM,
respectively), three times better than miltefosine against L.
donovani. Compound 5 also returned an IC50 value of 1.7 μM
against L. infantum axenic amastigotes, about two times lower
than fexinidazole. This compound also demonstrated promis-
ing activity against the promastigote stage of L. major (IC50 =
1.3 μM). Moreover, molecules 2 and 5 also demonstrated in
vitro activity against Trichomonas vaginalis (IC50 = 4.6−5.0
μM), comparable to that of the reference drug metronidazole
(IC50 = 4.2 μM). This eﬃcacy against T. vaginalis, also found
with fexinidazole,23 is probably due to similar modes of
bioactivation by parasitic nitroreductases.24 Nevertheless,
compared with atovaquone (IC50 = 1 nM), the activity of
Figure 1. Structure of previously reported hit molecules A and B in 3-
nitroimidazo[1,2-a]pyridine series.
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compound 5 against Plasmodium falciparum (K1 strain) is
negligible (IC50 = 19 μM), demonstrating its selectivity for the
parasites expressing nitroreductases. Finally, the in vitro
antitrypanosomal activity of compounds 2 and 5 were
evaluated against the bloodstream form of T. b. brucei and
the epimastigote form of T. cruzi and compared to reference
drugs (i.e., eﬂornithine, suramin, benznidazole, and nifurtimox)
and to drug candidate fexinidazole (Table 2). With IC50 values
ranging from 1.3 to 6.2 μM, these molecules showed a better
activity than eﬂornithine against T. b. brucei and a better
activity than fexinidazole against T. cruzi, while molecule 5 was
two times less active than drug candidate fexinidazole on T. b.
brucei and two times less active than benznidazole on T. cruzi.
Finally, the amino derivative 27 of hit-compound 5, prepared
by reduction of the nitro group, was tested in vitro (Table 3).
As expected, 27 did not show antileishmanial activity (IC50 =
32 to 124 μM) and presented a limited antitrypanosomal
activity (IC50 = 11 μM), in accordance with the hypothesis that
these nitroaromatic molecules require bioactivation by para-
sitic NTRs, making the nitro group a key element of the
pharmacophore.
To investigate the pharmaceutical potential of compound 5
(best molecule in the series) further, its microsomal stability
was measured after incubation with hepatic microsomes
isolated from female mice. Molecule 5 exhibited a poor
stability with a half-life (T1/2 of propranolol control = 26 min)
of 3 min. An LC/MS/MS study (see Supporting Information)
enabled us to identify that the primary metabolite of 5 was a
sulfoxide derivative. This sulfoxide metabolite (28) was then
synthesized from 5, along with a probable secondary sulfone
metabolite (29), respectively, by partial or complete oxidation
of the sulfur atom, using m-CPBA (Table 3). The activities of
metabolite 28 and molecule 29 were evaluated in vitro against
Leishmania spp and T. b. brucei. Both molecules demonstrated
promising activity against the promastigote stage of L. donovani
and of L. infantum axenic amastigotes. Likewise, both
molecules also demonstrated antitrypanosomal activity, thus
compound 5 appears to resemble fexinidazole in that it is
similarly metabolized into bioactive sulfoxide and sulfone
derivatives.13 These results suggest that the poor microsomal
stability of 5 should not be a barrier to further in vivo
evaluation.
The mutagenicity of many nitroaromatic molecules has been
known for many years.25 Nevertheless, considering the
therapeutic potential of these molecules, many attempts have
been made to dissociate their anti-infective activity from their
mutagenic character.26 However, the diﬃculty remains that the
anti-infective mechanism(s) of these compounds involves the
formation of mutagenic derivatives within microorganisms.27
The Salmonella typhimurium strains used in the Ames test, the
most common method for assessing the mutagenicity of a
substance, also express nitroreductases,28 particularly type 1.
This may explain why nitrated molecules are generally
identiﬁed as mutagens in this test. The mutagenic properties
of hit A, molecule 5, and sulfoxide metabolite 28 were then
evaluated by the Ames test, using four classical strains of S.
typhimurium expressing NTRs, both with and without addition
of the metabolizing S9 mixture. Hit A shows a mutagenic
character in the absence of S9 mix on each strain of S.
typhimurium, as well as on the TA97a strain in metabolizing
conditions. Interestingly, the Ames test was negative on all four
strains of Salmonella exposed to molecules 5 or 28, with or
without S9 mix (Table 4). Molecules 5 and its principal
metabolite 28 therefore appeared as nonmutagenic nitro-
aromatic derivatives in the Ames test. Thus, the introduction of
a p-chlorophenylthioether group at position 8 of the
imidazo[1,2-a]pyridine ring, along with the oxidation of the
sulfur atom, seem to favor selectivity for parasitic NTRs.
To complete the toxicological proﬁle of hit compound 5, a
comet assay using a HepG2 human hepatic cell line, which
does not express any NTR, was carried out on hit A and
molecule 5. HepG2 cells were incubated with the drugs for 2
Table 1. Synthesis, in Vitro Antileishmanial Activity, and
Cytotoxicity of 3-Nitroimidazopyridine Derivatives 1−26a
Cmpd R-
L. donovani
promastigotes
IC50 (μM)
cytotoxicity
HepG2 CC50
(μM)
selectivity
indexf
1 C6H5- 1.7 ± 0.1 >3.9
d >2.3
2 4-Br-C6H4- 1.0 ± 0.3 >62.5
d >62.5
3 2-Cl-C6H4- 1.4 ± 0.3 >5
d >3.6
4 3-Cl-C6H4- 0.7 ± 0.1 >3.9
d >3.6
5 4-Cl-C6H4- 1.0 ± 0.3 >100
d >100
6 2-F-C6H4- 1.2 ± 0.3 >5
d >4.2
7 3-F-C6H4- 1.2 ± 0.2 >3.9
d >2.1
8 4-F-C6H4- 1.3 ± 0.3 >5
d >3.8
9 2-CH3O-C6H4- 2.3 ± 0.2 >50
d >21.7
10 3-CH3O-C6H4- 2.3 ± 0.4 >15.6
d >6.8
11 4-CH3O-C6H4- 1.5 ± 0.3 >62.5
d >41.7
12 2-CF3-C6H4- 1.5 ± 0.3 >4.1
d >2.7
13 3-CF3-C6H4- 1.3 ± 0.2 >3.9
d >2.4
14 4-CF3-C6H4- 2.1 ± 0.3 >3.9
d >1.5
15 2-CH3-C6H4- 1.7 ± 0.3 >3.9
d >1.5
16 3-CH3-C6H4- 1.4 ± 0.2 >5.6
d >4
17 4-CH3-C6H4- 1.4 ± 0.2 >3.9
d >2.2
18 4-iprop-C6H4- 1.6 ± 0.1 >25
d >15.6
19 4-
(CH2COOH)-
C6H4-
65.6 ± 1.3 >62.5d >1
20 2,3-di-Cl-C6H3- 2.0 ± 0.1 >25
d >12.5
21 2,4-di-Cl-C6H3- 1.7 ± 0.1 >3.9
d >2.2
22 2,5-di-Cl-C6H3- 1.3 ± 0.1 >3.9
d >1.5
23 C6H5-CH2- NS
g NSg -
24 4-Br-C6H4−
CH2-
NSg NSg -
25 4-Cl-C6H4−
CH2-
NSg NSg -
26 4-CH3O-C6H4-
CH2-
NSg NSg -
amphotericin Bc 0.07 ± 0.01 8.8 ± 0.2 125.7
miltefosinec 3.1 ± 0.2 85 ± 8.8 27.4
pentamidinec 6.0 ± 0.8 2.3 ± 0.5 0.4
fexinidazolec 1.2 ± 0.20 >200e >166.7
doxorubicinb - 0.2 ± 0.05 -
aReagents and conditions: thiophenol or benzylthiol reagent (1
equiv), NaH (1 equiv), DMSO, N2, RT, 0.5−2 h.
bDoxorubicin was
used as a cytotoxic reference drug. cAmphotericin B, Miltefosine,
Pentamidine, and Fexinidazole were used as antileishmanial reference
drugs. dThe product could not be tested at higher concentrations in
the culture medium. eThe CC50 value was not reached at the highest
tested concentration. fSI = CC50 HepG2/IC50 L. donovani
promastigote. gNS = nonsoluble in the culture medium. In bold: hit
molecules.
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or 72 h (Table 4). No increase in the percentage of DNA
laddering was observed for these two compounds at the three
tested concentrations: 1, 10, and 20 μM (see Supporting
Information). These molecules are therefore not genotoxic
according to this test. This assay reveals, for hit A, a proﬁle
identical to fexinidazole or metronidazole: a mutagenic
character shown by the Ames test and no genotoxic properties
objectiﬁed on mammalian cells (micronucleus test or comet
assay).29 However, molecule 5 was neither mutagenic nor
genotoxic.
Among the accepted criteria for the selection of antiparasitic
candidate for preclinical evaluation,30 the percentage of
albumin binding may aﬀect both the distribution and the
elimination of the molecule under consideration. The binding
percentage to human albumin of compound 5 was measured
by LC/MS, after incubation in the presence of human plasma,
and compared with four reference drugs. With a bound
fraction of 99.95% (log(fu) = −3.28), this molecule is therefore
strongly bound to albumin (Table 4). The chromatographic
hydrophobicity index (CHI) of molecule 5 was also
determined and provides a logD7.4 value of 4.26, making this
molecule very lipophilic, in accordance with a high albumin
binding (Table 4). However, the binding of a drug to plasma
proteins was shown to have little eﬀect on the in vivo eﬃcacy of
this drug when its mechanism of action results in a covalent
binding to its target,31 which is the likely mode of action
proposed for anti-infective nitroaromatics. Moreover, the high
lipophilicity of 5 may facilitate its activity against the
amastigote stage, by increasing its penetration into both
macrophages and parasites.
In order to check that compounds 5 and 29 were substrates
of parasitic NTRs, their IC50 values were determined on three
strains of L. donovani promastigotes: a wild type strain, a strain
overexpressing NTR1, and a strain overexpressing NTR2. The
IC50 of 5 and 29 are about eight times lower in the strain
overexpressing NTR1 than the two other strains (Table 4).
These data demonstrate that these compounds are selectively
bioactivated by NTR1 in L. donovani, the same type 1
Table 2. In Vitro Antiparasitic Proﬁle of Compounds 2 and 5 toward Kinetoplastids
Cmpd
L. donovan
intramacrophage
amastigotes IC50 (μM)
L. infantum axenic
amastigotes IC50
(μM)
L. major
promastigotes
IC50 (μM)
L. major
intramacrophage
amastigotes IC50
(μM)
T. brucei brucei
trypanosomes IC50
(μM)
T. cruzi
epimastigotes
IC50 (μM)
THP1
CC50
(μM)
2 3.5 ± 0.3 9.0 ± 1.4 1.3 ± 0.2 5 3.8 ± 0.45 6.2 ± 1.9 >62.5e
5 1.3 ± 0.1 1.7 ± 0.3 1.3 ± 0.2 2.1 ± 0.1 1.3 ± 0.11 2.2 ± 0.08 >62.5e
amphotericin Ba 0.4 ± 0.01 0.06 ± 0.001 0.6 ± 0.08 0.2 ± 0.07 - - 3.6 ± 0.7
miltefosinea 4.3 ± 1.7 0.8 ± 0.2 - - - - >40e
fexinidazolea,b,c >50d 3.4 ± 0.8 - - 0.6 ± 0.05 8.9 ± 0.7 >62.5d
eﬂornithineb - - - - 13.3 ± 2.1 - -
suraminb - - - - 0.03 ± 0.004 - -
benznidazolec - - - - - 1.2 ± 0.1 -
nifurtimoxc - - - - - 0.3 ± 0.02 -
aAmphotericin B, miltefosine, and fexinidazole were used as antileishmanial reference drugs. bEﬂornithine, suramin, and fexinidazole were used as
anti-T. b. brucei reference drugs. cFexinidazole, benznidazole, and nifurtimox were used as anti-Trypanosoma cruzi reference drugs. dMolecule was
not tested at higher concentrations. eMolecules could not be tested at higher concentrations because of a lack of solubility in the culture media.
Table 3. Synthesis of Imidazopyridine Derivatives 27, 28
(Metabolite), and 29 and Their Biological Activitiesa
Cmpd
L. donovani
pro. IC50
(μM)
L. infantum axe.
ama. IC50 (μM)
T. brucei brucei
trypo. IC50 (μM)
HepG2
CC50
(μM)
5 1.0 ± 0.3 1.7 ± 0.3 1.3 ± 0.45 >100
27 124.0 ± 1.1 31.6 ± 2.7 10.6 ± 1.2 >62.5b
28 1.3 ± 0.3 1.6 ± 0.4 0.6 ± 0.11 >12.5b
29 1.3 ± 0.3 3.7 ± 0.5 1.0 ± 0.05 >12.5b
aReagents and conditions: (a) Fe (10 equiv), AcOH, reﬂux, 40 min;
(b) mCPBA (1 equiv), DCM, 0 °C, 3 h; (c) mCPBA (2 equiv),
DCM, RT, 24 h. bCompounds could not be tested at higher
concentrations due to a poor aqueous solubility.
Table 4. Complementary in Vitro Biological Evaluations for
Molecules 5, 28, and 29
molecule 5
Ames test (at 250 μM and 2.5 mM ± S9 mix) negative
Comet assay (at 2 and 72 h; 1, 10, and 20 μM) negative
CHI LogD7.4 4.26
thermodynamic aqueous solubility (μM) 1.4
binding % to human albumin 99.95
microsomal stability: t1/2 (min) 3
IC50 L. donovani promastigote wild-type strain (μM) 0.26
IC50 L. donovani promastigote NTR1 overexpressing strain (μM) 0.033
IC50 L. donovani promastigote NTR2 overexpressing strain (μM) 0.3
molecule 28
Ames test (at 62.5 and 625 μM ± S9 mix) negative
molecule 29
IC50 L. donovani promastigote wild-type strain (μM) 0.6
IC50 L. donovani promastigote NTR1 overexpressing strain (μM) 0.08
IC50 L. donovani promastigote NTR2 overexpressing strain (μM) 0.7
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nitroreductase that is responsible for the bioactivation of
fexinidazole and its associated metabolites.
On the basis that molecules 5, 28, and 29 could be
substrates of parasitic nitroreductases, we determined their
reduction potential to examine whether the absence of
mutagenicity of molecules 5 and 28 (and probable selectivity
for L. donovani NTR1 versus S. typhimurium NTRs) was
associated with a lower reduction potential. For the three
tested molecules (as for the two hit molecules A and B), the
cyclic voltammogram showed a reversible single electron
reduction for a 1 V·s−1 scan rate, corresponding to the
formation of a nitro radical anion. The measured reduction
potentials of compounds 5, 28, and 29 ranged from −0.63 to
−0.59 V/NHE. As expected, the more oxidized the sulfur atom
in position 8, the higher the reduction potential (Figure 2).
Nonmutagenic molecules 5 and 28 presented a lower
reduction potential than mutagenic Hit A, but the diﬀerence
in E° values was not signiﬁcant. Thus, steric parameters should
be explored in order to explain the atypical behavior of the
current series that is selectively bioactivated by L. donovani
NTR1 and not by S. typhimurium type 1 NTR. These data
suggest that the introduction of a thiophenyl moiety at position
8 of the scaﬀold maintains aﬃnity for the parasitic type 1 NTR
while decreasing the aﬃnity for the bacterial counterpart.
Finally, a preliminary in vivo toxicity study was conducted on
swiss mice (three mice per group) that were treated by
intraperitoneal administration (50 μL) of molecule 5 at either
1 (group 1) or 10 (group 2) mg/kg for 5 days. There was no
sign of acute toxicity noted on living mice. In each group, a
mouse was sacriﬁced at D7, D15, or D30 and autopsied.
Histology analysis (brain, liver, kidney, spleen, heart, lung,
adipose tissues, and muscles) did not reveal any sign of chronic
toxicity in group 1. In group 2, only a discrete inﬂammatory
inﬁltrate was detected in the liver, classiﬁed as nonspeciﬁc, and
a hypodermic lymph node was observed in the skin in addition
to some ﬁbrosis and inﬂammation at the injection site (see
Supporting Information).
In summary, introducing a para-chlorophenylthioether
moiety at position 8 of the antileishmanial 3-nitroimidazo-
[1,2-a]pyridine pharmacophore led to hit molecule 5 that
displayed improved in vitro antikinetoplastid activity against
both Leishmania (donovani and infantum) and Trypanosoma
(brucei brucei and cruzi) parasites, in comparison with the
previously identiﬁed hit molecules in the series. Moreover, 5
was the ﬁrst compound in the series that was neither
mutagenic nor genotoxic. It presented a short microsomal
half-life due to transformation into the sulfoxide metabolite
(28) that remains active and nonmutagenic. Hit compound 5
presents a low reduction potential and is selectively
bioactivated by L. donovani NTR1. These results make
molecule 5 a good candidate for a hit to lead program focused
on developing novel and safe nitroaromatic drug candidates
that selectively target ﬂagellated protozoans.
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(3) Peŕez-Molina, J. A.; Molina, I. Chagas Disease. Lancet 2018, 391,
82−94.
(4) (a) World Health Organization (WHO). http://www.who.int/
neglected_diseases/diseases/en/. (b) http://www.who.int/
healthinfo/global_burden_disease/en/. (c) http://www.who.int/
chagas/en/.
(5) Bilbe, G. Overcoming neglect of kinetoplastid diseases. Science
2015, 348 (6238), 974−976.
(6) Silva, D. G.; Gillespie, J. R.; Ranade, R. M.; Herbst, Z. M.;
Nguyen, U. T. T.; Buckner, F. S.; Montanari, C. A.; Gelb, M. H. New
class of antitrypanosomal agents based on imidazopyridines. ACS
Med. Chem. Lett. 2017, 8 (7), 766−770.
(7) Konstantinovic,́ J.; Videnovic,́ M.; Orsini, S.; Bogojevic,́ K.;
D’Alessandro, S.; Scaccabarozzi, D.; Jovanovic,́ N. T.; Gradoni, L.;
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